<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902023000400208</article-id>
<article-id pub-id-type="doi">10.29262/ram.v70i4.1308</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Introducción en alergia alimentaria]]></article-title>
<article-title xml:lang="en"><![CDATA[Introduction to food allergy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ansotegui Zubeldia]]></surname>
<given-names><![CDATA[Ignacio Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fiocchi]]></surname>
<given-names><![CDATA[Alessandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Quironsalud Departamento de Alergia e Inmunología ]]></institution>
<addr-line><![CDATA[Bilbao ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Bambino Gesú IRCCS Allergy division ]]></institution>
<addr-line><![CDATA[Roma ]]></addr-line>
<country>Italia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>70</volume>
<numero>4</numero>
<fpage>208</fpage>
<lpage>210</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902023000400208&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902023000400208&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902023000400208&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La alergia alimentaria es un trastorno crónico frecuente que afecta a lactantes, niños, adolescentes y adultos. La prevalencia de alergia alimentaria se ha incrementado en las últimas décadas en todo el mundo, sin limitarse a los países occidentales. Puesto que no existe ningún tratamiento, éste se centra en evitar los alergenos, además de la educación de pacientes y cuidadores en el tratamiento de urgencia de las reacciones agudas, por ejemplo: aplicación de epinefrina. Los estudios sugieren que las reacciones accidentales ocurren en alrededor del 45% de los niños con alergia alimentaria cada año, aunque la mayor parte de las reacciones son de gravedad leve o moderada. Los ingresos hospitalarios por anafilaxia alimentaria varían de 4 a 20 por cada 100,000 habitantes; las muertes son raras, con una incidencia estimada de 0.03 a 0.3 por cada millón de personas con alergia alimentaria. La muerte por anafilaxia alimentaria es rara y parece haberse mantenido estable, posiblemente por el aumento en el etiquetado de alérgenos alimentarios, los servicios de diagnóstico, las tasas de prescripción de epinefrina intramuscular y la concienciación acerca de alergias alimentarias. Omalizumab es un fármaco aprobado para varias alteraciones (urticaria crónica o asma difícil) y puede ayudar a reducir los síntomas asociados con la alergia alimentaria. La importancia relativa de las tecnologías alternativas, las estrategias de gestión y las políticas para la alergia alimentaria varía de una región a otra, debido a las diferencias en la epidemiología, educación, bienestar socioeconómico y preferencias culturales de la población.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Food allergy is a common chronic disorder that affects infants, children, adolescents, and adults. The prevalence of food allergy has increased in recent decades throughout the world, not limited to Western countries. Since there is no treatment, this focuses on avoiding allergens, in addition to educating patients and caregivers in the emergency treatment of acute reactions, for example: application of epinephrine. Studies suggest that accidental reactions occur in about 45% of children with food allergies each year, although most reactions are mild or moderate in severity. Hospital admissions for food anaphylaxis vary from 4 to 20 per 100,000 inhabitants; Deaths are rare, with an estimated incidence of 0.03 to 0.3 per million people with food allergy. Death from food anaphylaxis is rare and appears to have remained stable, possibly due to increases in food allergen labeling, diagnostic services, rates of intramuscular epinephrine prescription, and awareness of food allergies. Omalizumab is a drug approved for several disorders (chronic hives or difficult asthma) and may help reduce symptoms associated with food allergy. The relative importance of alternative technologies, management strategies and policies for food allergy varies from one region to another, due to differences in the epidemiology, education, socioeconomic well-being, and cultural preferences of the population.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Alergia alimentaria]]></kwd>
<kwd lng="es"><![CDATA[alérgenos]]></kwd>
<kwd lng="es"><![CDATA[Anafilaxia]]></kwd>
<kwd lng="es"><![CDATA[Epinefrina]]></kwd>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[Food allergy]]></kwd>
<kwd lng="en"><![CDATA[Allergens]]></kwd>
<kwd lng="en"><![CDATA[Anaphylaxis]]></kwd>
<kwd lng="en"><![CDATA[Epinephrine]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and burden of food allergy]]></article-title>
<source><![CDATA[Current Allergy and Asthma Rep]]></source>
<year>2020</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fiocchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dahdah]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Food allergy trends at the crossing among socio- economics, history and geography]]></article-title>
<source><![CDATA[Curr Opin Allergy Clin Immuno]]></source>
<year>2018</year>
<volume>18</volume>
<page-range>271-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McWilliam]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Koplin]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Self-reported adverse food reactions and anaphylaxis in the SchoolNuts study: a population-based study of adolescents.]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2018</year>
<volume>141</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>982-90</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Community-based adverse food reactions and anaphylaxis in children with IgE-mediated food allergy at age 6 years: a population-based study.]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2020</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3515-24</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mullins]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dear]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes in Australian food anaphylaxis admission rates following introduction of updated allergy prevention guidelines.]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2022</year>
<volume>150</volume>
<page-range>140-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[National Institute for Health and Care Excellence. Palforzia for treating peanut allergy in children and young people (TA 769). Published]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[Institute for Clinical and Economic Review. Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: Effectiveness and Value. 2019. California Technology Assessment Forum; United States of America]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<collab>Palforzia - EPAR Medicines Overview. Published</collab>
<source><![CDATA[]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bégin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy]]></article-title>
<source><![CDATA[Allergy Asthma Clin Immunol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-45</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pajno]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2018</year>
<volume>73</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>799-815</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brozek]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Firmino]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow`s Milk Allergy (DRACMA) Guideline update-XIV-Recommendations on CMA immunotherapy]]></article-title>
<source><![CDATA[World Allergy Org J]]></source>
<year>2022</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>100646</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fiocchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vickery]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of biologics in food allergy]]></article-title>
<source><![CDATA[Clin Exp Allergy]]></source>
<year>2021</year>
<volume>51</volume>
<numero>58</numero>
<issue>58</issue>
<page-range>1006-18</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandström]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vetander]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents]]></article-title>
<source><![CDATA[Clin Exp Allergy]]></source>
<year>2019</year>
<volume>49</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1328-41</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arasi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mennini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab as monotherapy for food allergy]]></article-title>
<source><![CDATA[Current Opin Allergy Clin Immunol]]></source>
<year>2021</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>286-91</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayats-Vidal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Riera-Rubió]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcome of omalizumab-assisted desensitisation to cow`s milk and eggs in patients refractory to conventional oral immunotherapy: real-life study]]></article-title>
<source><![CDATA[Allergol Immunopathol]]></source>
<year>2022</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
